Trans women do not cause HRT shortages. Estradiol and other hormone medications are in short supply due to manufacturing disruptions, demand forecasting failures, and supply chain pressures, not because trans women are consuming a menopausal supply. The claim is false, and it does real harm to both trans women and menopausal people who need the same medication.
Where did this claim come from?
Over the past few years, menopausal people across the UK, Europe, the United States, and beyond have faced real and distressing difficulty getting their hormone replacement therapy. Patches, gels, and oral tablets have all been affected at various points. That frustration is completely legitimate: going without oestrogen when you need it has genuine health consequences, and nobody should have to fight for a prescription they rely on.
Into that frustration stepped a narrative. The suggestion, circulated in newspaper columns, on social media, and occasionally in political speeches, was that trans women were hoovering up the same estradiol supply that menopausal women depend on, and that the shortage was, at least in part, their fault. Some versions of the claim were more careful, framing it as a concern about competing demand. Others were blunter. A few were openly hostile.
The problem is that the claim does not hold up to scrutiny. Not even slightly.
What is actually causing the HRT shortage?
Pharmaceutical supply shortages are rarely caused by a single factor, and this one is no different. What the evidence points to is a cluster of structural problems that have nothing to do with which patients are prescribed estradiol.
Manufacturing capacity is the clearest part of the picture. For years, the major manufacturers of hormone replacement medications underestimated future demand. When prescribing rates began to rise, including as a result of updated menopause guidance and wider public conversations about the benefits of HRT, production lines simply could not scale up quickly enough. Pharmaceutical manufacturing is not a tap you turn on overnight: new capacity requires regulatory approval, capital investment, and lead times measured in years.
Supply chain disruption has compounded this. The same global pressures that affected medication availability across many therapeutic areas, including active pharmaceutical ingredient shortages, shipping delays, and energy cost pressures, hit hormone medications alongside everything else.
Regulatory factors have also played a role. Changes in how specific formulations are classified, licensed, or supplied in different markets have at times created regional shortfalls even when global supply was technically adequate.
None of this is about trans women.
What do the numbers actually show?
The general prescribing picture shows, consistently, that trans women represent a small fraction of the total oestrogen prescribing market. Menopausal HRT is prescribed at scale across entire adult female populations. The idea that a comparatively small number of trans women's prescriptions could materially deplete that supply does not follow from any realistic reading of the numbers.
When the actual causes of shortage are traced, they lead to pharmaceutical companies, supply chains, and forecasting failures, not to a minority population of trans women whose oestrogen needs are, in any case, often met through formulations, doses, and routes of administration that differ from standard menopausal HRT.
It is also worth noting that many trans women use oestrogen at doses and in formulations that are not routinely prescribed for menopause at all, and that trans healthcare is often served through private prescribing rather than public supply chains in many countries. The picture of trans women and menopausal women fighting over an identical pot of medication is not how the supply chain actually works.
Why does this narrative keep circulating?
Because it is doing a job. A shortage with structural, systemic causes is difficult to be angry about. Pharmaceutical manufacturing capacity and demand forecasting failures are not satisfying targets for public frustration. A visible minority group, already the subject of intense political scrutiny, is a much easier focal point.
This is a pattern I have seen many times in trans healthcare debates: a real problem that affects many people is reframed so that trans people appear to be the cause. In doing so, it turns two groups who both face genuine healthcare access difficulties into apparent adversaries. Menopausal people and trans women both need oestrogen. They are not in competition. They are both poorly served by a pharmaceutical system that has not invested adequately in the medications they rely on.
The narrative also conveniently sidesteps the access barriers trans women themselves face. Trans women seeking oestrogen on public services in many countries face waiting lists measured in years, referral bureaucracy, and frequent refusals at the GP level. Trans women who access oestrogen privately face cost barriers and a marketplace that is poorly regulated in some jurisdictions. The idea that trans women have somehow seized an unfair supply advantage is the opposite of the lived reality most trans women describe to me.
What are the real access barriers for trans women?
Many trans women tell me that getting oestrogen prescribed is one of the hardest parts of their early transition. Public gender services in the UK, for example, have waiting lists running to several years in some areas. In the meantime, a trans woman who cannot access any oestrogen at all is not competing with anyone for supply: she is simply going without.
Those who do access oestrogen through gender services or private providers often face prescription refusals when they try to have those prescriptions continued by a general practitioner. The shared care model, in which a specialist initiates treatment and a GP continues it, breaks down when GPs decline to prescribe, citing uncertainty or discomfort. That leaves trans women in a cycle of private cost, interruptions to treatment, and health consequences from undertreated dysphoria and inadequate hormone support.
This is the real access story for many trans women on oestrogen. It is not a story of easy, abundant supply. It is a story of persistent barriers, gatekeeping, and fragmentation.
Does this mean menopausal people's concerns about supply are not valid?
No. Menopausal people's difficulty accessing HRT is real. Going without oestrogen during menopause has documented health consequences, and the frustration of facing a shortage of medication that your doctor has agreed you need is completely understandable. Those concerns deserve to be heard and acted on.
The point is that blaming trans women for that shortage misdirects the frustration. It does not solve the supply problem, which has structural causes that require structural solutions: investment in manufacturing, better demand forecasting, regulatory frameworks that reduce unnecessary supply chain friction. And it actively harms trans women, who are already a marginalised group facing real access difficulties of their own.
Solidarity between people who both need oestrogen, for different but equally legitimate reasons, is far more useful than competition built on a false premise.
How should clinicians and policymakers respond?
The practical response to HRT shortages is to address their actual causes. That means pressure on pharmaceutical manufacturers to invest in production capacity, better public procurement frameworks, prescribing flexibility that allows formulation substitution without requiring a new consultation, and transparency from regulators when shortages are anticipated.
It also means resisting the temptation to manage supply by restricting access for trans people. I have heard suggestions that trans women's oestrogen prescriptions should be deprioritised during shortages to preserve supply for menopausal people. That position is not grounded in supply data, it is not ethically defensible, and it would cause serious harm. Oestrogen is medically necessary for many trans women, just as it is medically necessary for many menopausal people. No clinical or ethical framework supports treating one group's medical need as less legitimate than another's.
For clinicians, the task is to prescribe clearly, document accurately, and push back when pharmacy or commissioning pressures are passed on to patients as individual rationing decisions. Patients should not be made to feel like a burden on supply.
What if you are struggling to access oestrogen right now?
If you are a trans woman or a non-binary person on oestrogen and you are having difficulty getting your prescription filled or continued, there are practical steps worth knowing about. Formulation flexibility matters: if one route of administration is in short supply, a different one may be available. Patches, gels, sprays, and oral tablets are not always interchangeable in dosing terms, but a knowledgeable prescriber can help you navigate that transition.
If your GP is refusing to continue a prescription initiated by a specialist, that refusal should be documented and challenged. Shared care guidance exists in many regions, and a refusal to prescribe an established medication with a clear clinical rationale is worth querying formally.
If public routes have closed to you or are taking too long, GenderGP at gendergp.com provides access to gender-affirming medical care from specialists who understand this territory and can work with you on the right approach for your situation.
Comments